Targeted opening of the blood–brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma

Jonathan Pol; Manuela Lizarralde-Guerrero; Andrea Checcoli; Guido Guido Kroemer

doi:10.1080/2162402x.2024.2385124

Abstract

1 min read

Doxorubicin is a prototypical inducer of immunogenic cell death (ICD) that sensitizes to subsequent immunotherapy by PD-1 blockade. However, this systemic drug combination fails against glioblastoma, hidden behind the blood-brain barrier (BBB). A recent work delineates a biophysical method for BBB permeabilization that yields effective preclinical effects of chemoimmunotherapy.

Related publications

Editorial Material2021

Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade

Guido Guido Kroemer, Oliver Kepp

Article2022

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer

Peng Liu, Jianzhou Chen, Liwei Zhao, Antoine Hollebecque, Oliver Kepp, Laurence Zitvogel, Guido Guido Kroemer

Article2024

The challenge and opportunity of gut microbiota‐targeted nanomedicine for colorectal cancer therapy

Yaohua Wei, Feng Shen, Huidong Song, Ruifang Zhao, Weiyue Feng, Yue Pan, Xiaobo Li, Huanling Yu, Giuseppe Familiari, Michela Relucenti, Michael Aschner, Hanping Shi, Rui Chen, Guangjun Nie, Hanqing Chen

Article2024

Blood–Brain Barrier-Penetrative Fluorescent Anticancer Agents Triggering Paraptosis and Ferroptosis for Glioblastoma Therapy

Jiefei Wang, Mingyue Cao, Lulu Han, Ping Shangguan, Yi‐Sheng Liu, Yong Zhong, Chaoyue Chen, Gaoyang Wang, Xiaoyu Chen, Ming‐Wei Lin, Mengya Lu, Zhengqun Luo, Mu He, Herman H. Y. Sung, Guangle Niu, Jacky W. Y. Lam, Bingyang Shi, Ben Zhong Tang

Preprint2024